• Press Releases
  • SENO Medical Instruments Announces $2 Million State Investment for Breast Cancer Detection Technology

Newsroom | Press Releases

SENO Medical Instruments Announces $2 Million State Investment for Breast Cancer Detection Technology

SAN ANTONIO, TEXAS — August 21, 2007 – Seno Medical Instruments, Inc., a company engaged in the development of medical devices announced a $2 million dollar award from the Texas Emerging Technology Fund (TETF). This funding will allow the company to further develop its life saving technology for cancer imaging and detection and move it closer to the global marketplace.

Texas Secretary of State Phil Wilson and Seno Medical Instruments, Inc. CEO Janet Campbell announced the Fund’s investment during a joint press conference at the world renowned Cancer Therapy and Research Center in San Antonio. The patented functional imaging technology will be commercialized to produce real-time color images which differentiate benign and malignant tumors, for all solid tumors, such as in breast cancer. Seno’s intent is to provide the most advanced high quality products for cancer screening, diagnosis and therapeutic treatment that are more humane than existing technologies.

“I am pleased that the state of Texas and its elected leadership recognize and support Seno’s technology, and our effort to create better tools for the detection and treatment of breast cancer. On behalf of my management team, we are grateful for the support we’ve received from our investors and organizations, not only in our hometown of San Antonio, but across Texas and the nation,” said Campbell.

The TETF is a $200 million program created by the Texas Legislature in 2005. A 17-member advisory committee of high-tech leaders, entrepreneurs and research experts reviews potential TETF projects and recommends funding for projects to the Governor, Lieutenant Governor and Speaker of the House. To date, the TETF has allocated $94.1 million in grant funds to Texas companies and universities across the state.

“Technological innovation is the lifeblood of today’s economy,” said Texas Governor Rick Perry. “Texas is making an important investment, literally, in the foundation of our future. By supporting advancing technology projects, such as breast cancer diagnostic devices, we are making a difference in a wide variety of products and services that enhance the quality of lives here today, and in the future.”
Seno Medical has selected the Cancer Therapy and Research Center and the University of Texas Health Science Center at San Antonio to conduct initial clinical studies.

More Seno Press Releases

Seno Medical® Receives Innovative Technology Contract from Vizient For its Imagio® Breast Imaging System
Contract awarded for products that bring improvement to healthcare industry [SAN ANTONIO, TX – November...
Real World Use of OA Imaging Confirms Clinical Acceptability of Second Generation Imagio® Breast Imaging System
[SAN ANTONIO, TX – October 31, 2024] A study published in Academic Radiology, Exploring the Utility of...
IHE SHARAZONE Hits Major Milestone with 15 Participants, Empowering 37 Creators and 24 Consumers
[May 17, 2024] IHE-Europe is thrilled to report a major milestone for the IHE SHARAZONE, a groundbreaking...
American Medical Association Issues New CPT Code for Use of Seno Medical’s Opto-acoustic Technology in Breast Cancer Diagnosis
CPT Code 0857T Enables a Pathway for Reimbursement When Using Seno’s Imagio® Breast Imaging System to Diagnose...
Seno Medical Earns Frost & Sullivan's 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis with Its Cutting-edge Technology
Seno Medical offers highly differentiated opto-acoustic/ultrasound (OA/US) exam to diagnose breast cancer...